Translational Development Acquisition

Translational Development Acquisition Financial Leverage

The Financial Leverage (Equity Multiplier) of Translational Development Acquisition (TDAC) as of Nov 4, 2026 is 1.04. In the previous year, Financial Leverage (Equity Multiplier) was 1.04 — a change of 0.05% (higher).

Financial Leverage

1.04

YoY

0.05%

Last updated:

Financial Leverage (Equity Multiplier) of Translational Development Acquisition is 2025 1.04 . Financial Leverage (Equity Multiplier) of Translational Development Acquisition was 2024 1.04 . It decreases by 0.05% higher compared to the previous year.

The Translational Development Acquisition Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2022
-19.78 USD
Jan 1, 2023
-0.00 USD
Jan 1, 2024
1.04 USD
Jan 1, 2025
1.04 USD
The Translational Development Acquisition Financial Leverage history
YEARFinancial LeverageYoY
1.04+0.05%
1.04-26,149.14%
-0.00-99.98%
-19.78—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Translational Development Acquisition Stock analysis

What does Translational Development Acquisition do? Translational Development Acquisition Corp is a blank check company formed to effect a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company has not selected any specific business combination target and has not engaged in any substantive discussions with potential targets. It has neither generated revenues nor conducted any operations since its formation. The firm's business model relies on identifying and executing a future business combination to create value for its shareholders. The company's primary revenue source will come from the successful completion of a business combination, which typically involves acquiring a target company or asset. As a blank check company, it does not operate any business or generate income until a merger or acquisition is finalized. The firm's investors, who purchase shares during its IPO, expect the company to identify and acquire a target business that will provide returns on their investment. Translational Development Acquisition Corp is structured as a special purpose acquisition company (SPAC) that has not yet identified a target business. Its success depends entirely on finding and merging with a suitable company within the timeframe specified in its prospectus. The firm's investors are the primary buyers of its shares, anticipating capital appreciation once a business combination is executed. Translational Development Acquisition is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Translational Development Acquisition stock

Financial Leverage (Equity Multiplier) of Translational Development Acquisition is 1.04 in 2025.

Financial Leverage (Equity Multiplier) of Translational Development Acquisition changed from 1.04 to 1.04, representing a 0.05% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) Translational Development Acquisition since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s Translational Development Acquisition with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Translational Development Acquisition

All Key Metrics — Translational Development Acquisition